Strategies for the Treatment of Parkinson's Disease: Beyond Dopamine

被引:78
|
作者
Iarkov, Alexandre [1 ]
Barreto, George E. [2 ,3 ]
Grizzell, J. Alex [4 ]
Echeverria, Valentina [1 ,5 ]
机构
[1] Univ San Sebastian, Fac Ciencias Salud, Lab Neurobiol, Concepcion, Chile
[2] Univ Limerick, Dept Biol Sci, Limerick, Ireland
[3] Univ Limerick, Hlth Res Inst, Limerick, Ireland
[4] Univ Colorado, Ctr Neurosci, Dept Psychol & Neurosci, Boulder, CO 80309 USA
[5] Bay Pines VA Healthcare Syst, Res & Dev Serv, Bay Pines, FL 33744 USA
来源
FRONTIERS IN AGING NEUROSCIENCE | 2020年 / 12卷
关键词
gene therapy; prevention; cotinine; stem cells; precision medicine; NICOTINIC ACETYLCHOLINE-RECEPTORS; DEEP-BRAIN-STIMULATION; STRIATAL CHOLINERGIC INTERNEURONS; STEM-CELL TRANSPLANTATION; IMPULSE CONTROL DISORDERS; DEPRESSIVE-LIKE BEHAVIOR; FREE-RADICAL THEORY; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; BASAL GANGLIA;
D O I
10.3389/fnagi.2020.00004
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Parkinson's disease (PD) is the second-leading cause of dementia and is characterized by a progressive loss of dopaminergic neurons in the substantia nigra alongside the presence of intraneuronal alpha-synuclein-positive inclusions. Therapies to date have been directed to the restoration of the dopaminergic system, and the prevention of dopaminergic neuronal cell death in the midbrain. This review discusses the physiological mechanisms involved in PD as well as new and prospective therapies for the disease. The current data suggest that prevention or early treatment of PD may be the most effective therapeutic strategy. New advances in the understanding of the underlying mechanisms of PD predict the development of more personalized and integral therapies in the years to come. Thus, the development of more reliable biomarkers at asymptomatic stages of the disease, and the use of genetic profiling of patients will surely permit a more effective treatment of PD.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Neurotransmission in Parkinson's disease: beyond dopamine
    Barone, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (03) : 364 - 376
  • [2] Dopamine agonist-based strategies in the treatment of Parkinson’s disease
    Angelo Antonini
    Paolo Barone
    Neurological Sciences, 2008, 29 : 371 - 374
  • [3] Dopamine agonist-based strategies in the treatment of Parkinson's disease
    Antonini, Angelo
    Barone, Paolo
    NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 5) : S371 - S374
  • [4] Dopamine agonists in the treatment of Parkinson's disease
    Bracco, F
    Delibori, D
    5TH CONGRESS OF THE EUROPEAN SOCIETY FOR CLINICAL NEUROPHARMACOLOGY, 2000, : 201 - 207
  • [5] Treatment strategies for Parkinson's disease
    Yuan, Hong
    Zhang, Zhen-Wen
    Liang, Li-Wu
    Shen, Quan
    Wang, Xiang-Dang
    Ren, Su-Mei
    Ma, Hong-Jie
    Jiao, Shu-Jun
    Liu, Ping
    NEUROSCIENCE BULLETIN, 2010, 26 (01) : 66 - 76
  • [6] Dopamine agonists - clinical applications beyond Parkinson's disease
    Kuran, Wlodzimierz
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2007, 41 (02) : S54 - S58
  • [7] Dopamine agonist treatment of Parkinson's disease in the elderly
    Isaacson, SH
    Kreitzman, DL
    MOVEMENT DISORDERS, 2004, 19 : S266 - S266
  • [8] The history of dopamine and levodopa in the treatment of Parkinson's disease
    Fahn, Stanley
    MOVEMENT DISORDERS, 2008, 23 : S497 - S508
  • [9] Dopamine agonists: their role in the treatment of Parkinson's disease
    Brooks, DJ
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (06): : 685 - 689
  • [10] Dual dopamine agonist treatment in Parkinson’s disease
    Fabrizio Stocchi
    Laura Vacca
    Alfredo Berardelli
    Marco Onofrj
    Mario Manfredi
    Stefano Ruggieri
    Journal of Neurology, 2003, 250 : 822 - 826